PARP Inhibitors Might Treat Two Rare Cancers

Researchers from Yale Cancer Center have found that PARP Inhibitors might offer an effective treatment paradigm for two rare inherited cancers, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and Succinate Dehydrogenase-related Hereditary Paraganglioma and Pheochromocytoma (SDH PGL/PCC).

The findings were published in Nature Genetics.

Both of these cancers are the result of abnormally high metabolite levels and are caused by inherited gene mutations that code for enzymes that process the metabolites. The researchers found that high levels of metabolites degrade homologous recombination, which is a way cells repair their DNA damage.

The researchers are now planning a clinical trial to evaluate PARP inhibitors in patients with the two cancers.

Joel T. Nowak, MA, MSW wrote this Post.  Joel is the CEO/Executive Director of Cancer ABCs.  He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.